Education
About Us
Working with TipRanks
Follow Us
Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Total Valuation
Sunshine Biopharma has a market cap or net worth of $6.56M. The enterprise value is -$1.86M.
Market Cap$6.56M
Enterprise Value-$1.86M
Share Statistics
Sunshine Biopharma has 4,555,945 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,555,945
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sunshine Biopharma’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -22.73%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-22.73%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee670.65K
Profits Per Employee-98.73K
Employee Count52
Asset Turnover1.14
Inventory Turnover2.15
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.05
Price to Fair Value0.09
Price to FCF-0.47
Price to Operating Cash Flow-0.08
PEG Ratio>-0.01
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 34.87M and earned -5.13M in profits. Earnings per share was -7.32.
Revenue34.87M
Gross Profit10.67M
Operating Income-5.81M
Pretax Income-5.37M
Net Income-5.13M
EBITDA-5.15M
Earnings Per Share (EPS)-7.32
Cash Flow
In the last 12 months, operating cash flow was -12.53M and capital expenditures -2.23M, giving a free cash flow of -14.76M billion.
Operating Cash Flow-12.53M
Free Cash Flow-14.76M
Free Cash Flow per Share-3.24
Dividends & Yields
Sunshine Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-69.87%
50-Day Moving Average1.51
200-Day Moving Average2.16
Relative Strength Index (RSI)39.71
Average Volume (3m)146.34K
Important Dates
Sunshine Biopharma upcoming earnings date is Jul 30, 2025, After Close (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
Sunshine Biopharma as a current ratio of 4.11, with Debt / Equity ratio of 4.05%
Current Ratio4.11
Quick Ratio2.33
Debt to Market Cap0.00
Net Debt to EBITDA1.69
Interest Coverage Ratio-662.43
Taxes
In the past 12 months, Sunshine Biopharma has paid -235.00K in taxes.
Income Tax-235.00K
Effective Tax Rate0.04
Enterprise Valuation
Sunshine Biopharma EV to EBITDA ratio is 1.29, with an EV/FCF ratio of 0.45.
EV to Sales-0.19
EV to EBITDA1.29
EV to Free Cash Flow0.45
EV to Operating Cash Flow0.53
Balance Sheet
Sunshine Biopharma has $9.69M in cash and marketable securities with $952.48K in debt, giving a net cash position of -$8.73M billion.
Cash & Marketable Securities$9.69M
Total Debt$952.48K
Net Cash-$8.73M
Net Cash Per Share-$1.92
Tangible Book Value Per Share$29.19
Margins
Gross margin is 30.60%, with operating margin of -16.67%, and net profit margin of -14.72%.
Gross Margin30.60%
Operating Margin-16.67%
Pretax Margin-15.40%
Net Profit Margin-14.72%
EBITDA Margin-14.78%
EBIT Margin-15.42%
Analyst Forecast
The average price target for Sunshine Biopharma is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside386.11% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast35.51%
EPS Growth Forecast95.44%